GlassScriptPhysician profile
Shilpa Singh
NPI 1225598535
$3,469.98
in general payments reported to CMS, 2019-2025
18 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $352 · 2023: $1,481 · 2024: $1,270 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380 · Education: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.12 |
| Education | $737.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $697.94 | 2023-2025 | Emblem Mri S-Icd, Latitude Communicator Power Supply, General - Therapies |
| Abbott Laboratories | $588.75 | 2023-2025 | Ensite, Thoratec Heartmate 3 Lvas Implant Kit, Perclose Prostyle |
| Abiomed | $404.87 | 2022-2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $359.21 | 2022-2025 | Lifevest |
| Heartflow, INC. | $295.36 | 2022-2023 | Ffrct |
| Medtronic, INC. | $207.30 | 2024 | Micra, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Cvrx, INC. | $153.26 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $147.86 | 2023 | Brilinta, Wainua |
| Amgen INC. | $147.59 | 2023-2025 | Repatha |
| Pfizer INC. | $141.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $102.47 | 2024-2025 | |
| Lantheus Medical Imaging, INC. | $63.62 | 2023 | Definity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.40 | 2022-2025 | Jardiance |
| Scpharmaceuticals INC. | $22.98 | 2025 | |
| Terumo Medical Corporation | $20.83 | 2024 | Angio-Seal |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $18.94 | 2024 | Arcalyst |
| Chiesi USA, INC. | $17.71 | 2025 | Kengreal, Cleviprex |
| Kiniksa Pharmaceuticals, LTD. | $16.84 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpa Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.